Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. https://doi.org/10.3322/caac.21834.

Article  PubMed  Google Scholar 

Zhang N, Wu J, Wang Q, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;13(1):82. https://doi.org/10.1038/s41408-023-00853-3.

Article  PubMed  PubMed Central  Google Scholar 

Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 1990–2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging. 2022;14(7):3175–90. https://doi.org/10.18632/aging.204006.

Article  PubMed  PubMed Central  Google Scholar 

Wang SS. Epidemiology and etiology of diffuse large B-cell lymphoma. Semin Hematol. 2023;60(5):255–66. https://doi.org/10.1053/j.seminhematol.2023.11.004.

Article  PubMed  PubMed Central  Google Scholar 

Health Commission of the People’s Republic of China N. National guidelines for diagnosis and treatment of malignant lymphoma 2022 in China (English version). Chin J Cancer Res. 2022;34(5):425–46. https://doi.org/10.21147/j.issn.1000-9604.2022.05.01.

Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5. https://doi.org/10.1182/blood-2010-03-276246.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silkenstedt E, Salles G, Campo E, et al. B-cell non-Hodgkin lymphomas. Lancet. 2024;403(10438):1791–807. https://doi.org/10.1016/s0140-6736(23)02705-8.

Article  CAS  PubMed  Google Scholar 

Karsten IE, Shumilov E, Schmitz N, et al. Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs. Br J Haematol. 2024;205(6):2163–74. https://doi.org/10.1111/bjh.19860.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol. 2018;182(5):633–43. https://doi.org/10.1111/bjh.15412.

Article  PubMed  PubMed Central  Google Scholar 

Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141(5):467–80. https://doi.org/10.1182/blood.2021011994.

Article  CAS  PubMed  Google Scholar 

Zhang G, Deng L, Lu H, et al. Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies. Int J Clin Pharm. 2024;46(1):186–94. https://doi.org/10.1007/s11096-023-01670-1.

Article  PubMed  Google Scholar 

Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220–31. https://doi.org/10.1056/NEJMoa2206913.

Article  CAS  PubMed  Google Scholar 

Abramson JS, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024;404(10466):1940–54. https://doi.org/10.1016/s0140-6736(24)01774-4.

Article  CAS  PubMed  Google Scholar 

Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–28. https://doi.org/10.1111/j.1524-4733.2004.75003.x.

Article  PubMed  Google Scholar 

Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https://doi.org/10.1186/1471-2288-12-9.

Article  PubMed  PubMed Central  Google Scholar 

Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med. 2022;386(4):351–63. https://doi.org/10.1056/NEJMoa2115304.

Article  CAS  PubMed  Google Scholar 

Wu W, Zhou Y, Wang Y, et al. Value for money of CAR-T cell therapy for patients with diffuse large B-cell lymphoma in China: evidence from a cost-effectiveness analysis. Appl Health Econ Health Policy. 2023;21(5):773–83. https://doi.org/10.1007/s40258-023-00817-5.

Article  PubMed  Google Scholar 

Tkacz J, Garcia J, Gitlin M, et al. The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy. Leuk Lymphoma. 2020;61(7):1601–9. https://doi.org/10.1080/10428194.2020.1734592.

Article  CAS  PubMed  Google Scholar 

Li Z, Pan Z, Zhang L, et al. End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study. BMJ Open. 2019;9(3): e026309. https://doi.org/10.1136/bmjopen-2018-026309.

Article  PubMed  PubMed Central  Google Scholar 

Lin Z, Zuo C, Jiang Y, et al. Cost-effectiveness analysis of relmacabtagene autoleucel for relapsed or refractory large B-cell lymphoma in China. Value Health Reg Issues. 2023;37:41–8. https://doi.org/10.1016/j.vhri.2023.03.006.

Article  PubMed  Google Scholar 

Chen Q, Staton AD, Ayer T, et al. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59(7):1700–9. https://doi.org/10.1080/10428194.2017.1390230.

Article  PubMed  Google Scholar 

Yue X, Li Y, Wu J, et al. Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China. Value Health Reg Issues. 2021;24:1–5. https://doi.org/10.1016/j.vhri.2020.07.580.

Article  CAS  PubMed  Google Scholar 

Li N, Zheng B, Cai HF, et al. Cost-effectiveness analysis of axicabtagene ciloleucel vs. salvage chemotherapy for relapsed or refractory adult diffuse large B-cell lymphoma in China. Support Care Cancer. 2022;30(7):6113–21. https://doi.org/10.1007/s00520-022-07041-2.

Article  PubMed  Google Scholar 

Yang Y, Zhang Y, Wagner AK, et al. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: a cohort study based on national health insurance data. J Glob Health. 2023;13:04083. https://doi.org/10.7189/jogh.13.04083.

Article  PubMed  PubMed Central  Google Scholar 

Cai L, Tao T, Li H, et al. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: a controlled interrupted time series study. J Glob Health. 2022;12:11016. https://doi.org/10.7189/jogh.12.11016.

Article  PubMed  PubMed Central  Google Scholar 

Mingge X, Jingyu W, Qi L, et al. Promoting access to innovative anticancer medicines: a review of drug price and national reimbursement negotiation in China. Inquiry. 2023;60:469580231170729. https://doi.org/10.1177/00469580231170729.

Article  PubMed  Google Scholar 

Zhu Z, Zhang J, Xu Z, et al. Impacts of national reimbursement drug price negotiation on drug accessibility, utilization, and cost in China: a systematic review. Int J Equity Health. 2025;24(1):36. https://doi.org/10.1186/s12939-025-02390-w.

Article  CAS  PubMed  PubMed Central  Google Scholar